The Irish Pharmaceutical Sector in Ireland
An overview of how Ireland’s pharma industry is performing today, where its key risks lie, and what it means for the wider economy.
Pharma central to Ireland’s FDI-led growth model
The pharmaceutical sector sits at the heart of Ireland’s long-standing strategy of attracting major global multinationals for investment, jobs and economic progress. This strategy has been sustained across governments for decades, providing pivotal policy stability. The sector is materially more important to Ireland than other EU states. In 2025, pharma exports amounted to €139bn, representing 53% of all goods exports and 41% of GNI*. Around 75K workers are employed in pharma manufacturing and related activities (28K in manufacturing), placing Ireland among Europe’s most pharma-intensive economies. The sector also delivers important fiscal benefits, paying over 15% of corporation tax in 2024, with total tax contributions exceeding €6bn in 2023 (7% of total) and growing.
A mature, high-value cluster with a regional dimension
Over more than five decades Ireland has evolved from small‑molecule production host to a world‑class biologics and advanced‑therapeutics hub. Ireland now hosts operations of the top 15 global pharma companies and has the highest number of FDA‑registered sites per capita in Europe, with a concentration in the South-West and South-East. Ireland’s competitive edge continues to rest on talent and R&D support, but domestic infrastructure constraints (housing, water, electricity) are a threat to competitiveness. The short-term outlook for corporate tax revenues is positive and should be diverted to addressing these issues.
Trade policy uncertainty and GLP-1 behind recent export surge
Over 60% of Irish pharma exports went to the US in 2025, with the top three markets exceeding at 80%. Exports surged partly due to front‑running ahead of US trade announcements, but the structural driver is the explosive rise of GLP‑1 drugs. Ireland’s exports of hormone‑based components to the US nearly quadrupled, representing ~20% of all Irish goods exports in 2025.
Policy uncertainty remains, but focus on domestic priorities
US policy has turned more protectionist, yet the worst risks have not materialised: pharmaceuticals have again been exempted from the proposed 10% global tariff. Sixteen of seventeen major pharma companies have signed US agreements granting them a three‑year moratorium on any pharma tariffs. However, pricing pressures are intensifying via the “Most Favored Nation” (MFN) process and a push for domestic production. The latter provides a medium-term risk for Ireland. Ireland must guard its current strengths managing geopolitical shifts. Its long standing-relationship with the US put it in a good position to do so. Priorities include safeguarding tax competitiveness, ensuring infrastructure keeps pace with capacity, and pushing hard at EU level for faster regulation, stronger R&D funding and more venture investment. With global demand for biologics and GLP‑1s set to expand, Ireland is well positioned if policymakers move decisively to reduce concentration risks and reinforce the sector’s long‑term foundations.